Atossa Therapeutics, Inc. (ATOS)
2.42
-0.04
(-1.63%)
USD |
NASDAQ |
Oct 08, 16:00
2.43
+0.01
(+0.41%)
Pre-Market: 08:31
Atossa Therapeutics Net Income (Quarterly) : -8.491M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.491M |
| March 31, 2026 | -9.589M |
| December 31, 2025 | -10.94M |
| September 30, 2025 | -8.692M |
| June 30, 2025 | -8.423M |
| March 31, 2025 | -6.718M |
| December 31, 2024 | -6.347M |
| September 30, 2024 | -7.23M |
| June 30, 2024 | -6.049M |
| March 31, 2024 | -5.878M |
| December 31, 2023 | -7.754M |
| September 30, 2023 | -6.229M |
| June 30, 2023 | -9.83M |
| March 31, 2023 | -6.281M |
| December 31, 2022 | -7.491M |
| September 30, 2022 | -8.011M |
| June 30, 2022 | -6.672M |
| March 31, 2022 | -4.786M |
| December 31, 2021 | -4.832M |
| September 30, 2021 | -5.197M |
| June 30, 2021 | -7.039M |
| March 31, 2021 | -3.538M |
| December 31, 2020 | -7.483M |
| September 30, 2020 | -3.491M |
| June 30, 2020 | -3.906M |
| Date | Value |
|---|---|
| March 31, 2020 | -2.947M |
| December 31, 2019 | -2.618M |
| September 30, 2019 | -3.286M |
| June 30, 2019 | -7.262M |
| March 31, 2019 | -4.073M |
| December 31, 2018 | -2.078M |
| September 30, 2018 | -3.310M |
| June 30, 2018 | -4.143M |
| March 31, 2018 | -1.874M |
| December 31, 2017 | -1.993M |
| September 30, 2017 | -2.184M |
| June 30, 2017 | -2.242M |
| March 31, 2017 | -1.704M |
| December 31, 2016 | -2.524M |
| September 30, 2016 | 0.2047M |
| June 30, 2016 | -1.722M |
| March 31, 2016 | -2.328M |
| September 30, 2015 | -3.773M |
| June 30, 2015 | -3.122M |
| March 31, 2015 | -3.335M |
| December 31, 2014 | -5.813M |
| September 30, 2014 | -3.245M |
| June 30, 2014 | -3.188M |
| March 31, 2014 | -2.412M |
| December 31, 2013 | -2.758M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Immix Biopharma, Inc. | -11.56M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 8.491M |
| EPS Diluted (Quarterly) | -0.9531 |
| Enterprise Value | -2.054M |
| Earnings Yield | -179.5% |
| Normalized Earnings Yield | -179.53 |